TECX Stock Forecast: Tectonic Therapeutic, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$21

The median 12-month analyst price target for Tectonic Therapeutic, Inc. is $76. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$405.3M
Ticker Nerd rank
44/ 100
Median analyst target
$76
Analysts covering
10
Revenue$0.0
Operating income−$24.2M
Net income−$22.3M
Free cash flow−$21.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tectonic Therapeutic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Accruals
72
Momentum
57
Value
55
Revisions
49
Quality
46
Growth
25
Issuance
23

Volatility (78): The share price has been relatively steady.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TECX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says10 analysts
9
Buy
1
Hold
0
Sell
$26
Low
$76
Median
$93
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026UBSInitiatesNeutral$26
7 Aug 2026Wells FargoMaintainsOverweight$101 → $93
26 May 2026Raymond JamesUpgradeStrong Buy$76 → $81
14 Apr 2026StifelInitiatesBuy—
8 Jan 2026Truist SecuritiesMaintainsBuy—
3 Sept 2025OppenheimerInitiatesOutperform—
21 July 2025Truist SecuritiesInitiatesBuy—
11 June 2025Raymond JamesReinstatesOutperform$76
6 June 2025LifeSci CapitalInitiatesOutperform—
15 May 2025MizuhoMaintainsOutperform—
21 Apr 2025MizuhoInitiatesOutperform—
21 Mar 2025Wells FargoMaintainsOverweight—
31 Jan 2025Wells FargoMaintainsOverweight—
20 Nov 2024Raymond JamesInitiatesOutperform—
12 Nov 2024Wells FargoMaintainsOverweight—
11 Nov 2024Leerink PartnersMaintainsOutperform—
22 Aug 2024Wells FargoInitiatesOverweight—
24 July 2024Leerink PartnersInitiatesOutperform—
26 June 2024Piper SandlerInitiatesOverweight—
24 June 2024TD CowenInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TECX.

Market Radar

This page is one stock. Monday covers all of them.

TECX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

TECX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.8×

Cheaper than 47% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−35.5%

Higher than 26% of US stocks

Return on assets
−23.2%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tectonic Therapeutic, Inc. has a market value of $405.3M and an enterprise value of $182.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.8M.

  • Diluted earnings per share, trailing twelve months: −$4.57.

  • Free cash flow in the twelve months to 30 June 2026: −$72.4M.

  • Shares outstanding: 19.2M.

  • Tectonic Therapeutic, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

TECX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECXTectonic Therapeutic, Inc.$405.3M44
CRMDCorMedix, Inc.$410.8M63
OVIDOvid Therapeutics, Inc.$410.6M47
TVGNTevogen, Inc.$405.2M17
ARVNArvinas, Inc.$423.0M74
IRLAIRulya Therapeutics, Inc.$432.4M33
CADLCandel Therapeutics, Inc.$395.4M43

Take a look at TECX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tectonic Therapeutic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TECX

What is the TECX stock price forecast for 2026-2027?

The median 12-month analyst price target for Tectonic Therapeutic, Inc. is $76, with estimates ranging from $26 to $93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECX stock a buy right now?

Of the 10 analysts covering Tectonic Therapeutic, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tectonic Therapeutic, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECX?

As at 21 Nov 2026, Tectonic Therapeutic, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

Will TECX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $76, and Ticker Nerd's factor model ranks Tectonic Therapeutic, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECX stock forecast for 2030?

No analyst covering Tectonic Therapeutic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $93 over the next 12 months.

What does Tectonic Therapeutic, Inc. do?

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors, or GPCRs. Its work centers on the GEODe platform, which is designed to support the development of GPCR-targeted biologic medicines for diseases where traditional approaches have been difficult to advance.

Company

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors, or GPCRs. Its work centers on the GEODe platform, which is designed to support the development of GPCR-targeted biologic medicines for diseases where traditional approaches have been difficult to advance. The company’s current pipeline includes programs aimed at cardiovascular, fibrotic, and rare disease areas, including candidates such as TX45 and TX2100. Tectonic Therapeutic, Inc. operates in the broader drug discovery and biologics segment, where GPCR biology is an important but technically challenging area of therapeutic innovation. Based in Watertown, Massachusetts, the company focuses on advancing specialized protein and antibody-based medicines for current unmet medical needs.

CEO Dr. Alise S. Reicin M.D., Ph.D. · 60 employees · United States · https://tectonictx.com